Financial Ratios Vanda Pharmaceuticals Inc.
Equities
VNDA
US9216591084
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.810 USD | -5.17% |
|
+11.66% | -0.11% |
| 03-05 | Truist Initiates Vanda Pharmaceuticals at Buy With $18 Price Target | MT |
| 03-05 | Vanda Pharmaceuticals Insider Sold Shares Worth $1,276,971, According to a Recent SEC Filing | MT |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 4.68 | 0.64 | -1.36 | -3.9 | -16.5 | |||||
Return on Total Capital | 5.36 | 0.75 | -1.6 | -4.6 | -21.21 | |||||
Return On Equity % | 6.92 | 1.22 | 0.47 | -3.49 | -50.93 | |||||
Return on Common Equity | 6.92 | 1.22 | 0.47 | -3.49 | -50.93 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 90.46 | 90.45 | 92.32 | 94.31 | 93.96 | |||||
SG&A Margin | 46.17 | 53.65 | 58.6 | 73.66 | 110.11 | |||||
EBITDA Margin % | 16.75 | 3.56 | -5.68 | -16.36 | -66.2 | |||||
EBITA Margin % | 16.24 | 3.08 | -6.16 | -16.8 | -66.71 | |||||
EBIT Margin % | 15.69 | 2.49 | -7.24 | -20.46 | -69.95 | |||||
Income From Continuing Operations Margin % | 12.34 | 2.47 | 1.3 | -9.51 | -102.02 | |||||
Net Income Margin % | 12.34 | 2.47 | 1.3 | -9.51 | -102.02 | |||||
Net Avail. For Common Margin % | 12.34 | 2.47 | 1.3 | -9.51 | -102.02 | |||||
Normalized Net Income Margin | 9.85 | 2.78 | -0.8 | -9.41 | -40.69 | |||||
Levered Free Cash Flow Margin | 17.95 | 12.71 | -46.08 | -9.42 | -22.84 | |||||
Unlevered Free Cash Flow Margin | 17.95 | 12.71 | -46.08 | -9.42 | -22.84 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.48 | 0.41 | 0.3 | 0.3 | 0.38 | |||||
Fixed Assets Turnover | 19.92 | 21.78 | 19.16 | 18.22 | 16.5 | |||||
Receivables Turnover (Average Receivables) | 8.6 | 7.71 | 5.69 | 4.89 | 4.25 | |||||
Inventory Turnover (Average Inventory) | 22.24 | 21.89 | 11.6 | 7.34 | 7.29 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 6.43 | 5.68 | 4.94 | 4.39 | 2.39 | |||||
Quick Ratio | 6.25 | 5.47 | 4.82 | 4.22 | 2.19 | |||||
Operating Cash Flow to Current Liabilities | 0.86 | 0.35 | 0.15 | -0.16 | -0.75 | |||||
Days Sales Outstanding (Average Receivables) | 42.45 | 47.33 | 64.1 | 74.81 | 85.87 | |||||
Days Outstanding Inventory (Average Inventory) | 16.41 | 16.68 | 31.46 | 49.87 | 50.06 | |||||
Average Days Payable Outstanding | 14.2 | 101.62 | 241.99 | 166.71 | 116.93 | |||||
Cash Conversion Cycle (Average Days) | 44.67 | -37.61 | -146.42 | -42.03 | 19 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 2.45 | 2.11 | 1.73 | 2.3 | 3.86 | |||||
Total Debt / Total Capital | 2.39 | 2.07 | 1.7 | 2.24 | 3.71 | |||||
LT Debt/Equity | 1.99 | 1.67 | 1.29 | 1.5 | 2.16 | |||||
Long-Term Debt / Total Capital | 1.94 | 1.64 | 1.26 | 1.47 | 2.08 | |||||
Total Liabilities / Total Assets | 14.97 | 16.88 | 15.97 | 17.93 | 33.08 | |||||
Total Debt / EBITDA | 0.26 | 0.96 | -1.13 | -0.41 | -0.09 | |||||
Net Debt / EBITDA | -8.81 | -39.08 | 45.42 | 12.13 | 1.79 | |||||
Total Debt / (EBITDA - Capex) | 0.26 | 1.01 | -0.09 | -0.36 | -0.09 | |||||
Net Debt / (EBITDA - Capex) | -8.92 | -41.49 | 3.46 | 10.47 | 1.78 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 8.27 | -5.32 | -24.27 | 3.18 | 8.72 | |||||
Gross Profit, 1 Yr. Growth % | 8.12 | -5.33 | -22.71 | 5.41 | 8.32 | |||||
EBITDA, 1 Yr. Growth % | 49.51 | -79.86 | -220.75 | 197.28 | 339.8 | |||||
EBITA, 1 Yr. Growth % | 51.98 | -82.02 | -251.2 | 181.46 | 331.79 | |||||
EBIT, 1 Yr. Growth % | 54.8 | -84.99 | -320.45 | 191.43 | 271.79 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 42.06 | -81.07 | -60.02 | -853.29 | 1.07K | |||||
Net Income, 1 Yr. Growth % | 42.06 | -81.07 | -60.02 | -853.29 | 1.07K | |||||
Normalized Net Income, 1 Yr. Growth % | 33.83 | -73.33 | -129.51 | 1.12K | 370.33 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 38.1 | -81.03 | -63.64 | -925.02 | 1.03K | |||||
Accounts Receivable, 1 Yr. Growth % | 8.09 | 3.22 | 1.92 | 37.9 | 15.87 | |||||
Inventory, 1 Yr. Growth % | -19.92 | 16.49 | 13.65 | 27.19 | 7.3 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | -15.14 | -11.4 | -16.7 | 38.7 | 6.6 | |||||
Total Assets, 1 Yr. Growth % | 11.31 | 6.81 | 2.24 | 1.2 | -25.49 | |||||
Tangible Book Value, 1 Yr. Growth % | 12.31 | 4.91 | -16.73 | 0.21 | -50.5 | |||||
Common Equity, 1 Yr. Growth % | 11.4 | 4.41 | 3.36 | -1.17 | -39.25 | |||||
Cash From Operations, 1 Yr. Growth % | 24.03 | -50.19 | -59.98 | -223.09 | 594.56 | |||||
Capital Expenditures, 1 Yr. Growth % | -69.25 | 23.01 | 14.78K | -95.33 | -78.85 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 25.2 | -32.93 | -374.48 | -78.91 | 189.44 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 25.2 | -32.93 | -374.48 | -78.91 | 189.44 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 8.75 | 1.24 | -15.33 | -11.6 | 5.92 | |||||
Gross Profit, 2 Yr. CAGR % | 9.5 | 1.17 | -14.46 | -9.74 | 6.85 | |||||
EBITDA, 2 Yr. CAGR % | 32.33 | -45.13 | -50.69 | 89.46 | 261.58 | |||||
EBITA, 2 Yr. CAGR % | 33.97 | -47.73 | -47.87 | 106.3 | 248.61 | |||||
EBIT, 2 Yr. CAGR % | 35.96 | -51.8 | -42.48 | 153.46 | 229.16 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | -46.44 | -48.15 | -72.49 | 73.55 | 837.41 | |||||
Net Income, 2 Yr. CAGR % | -46.44 | -48.15 | -72.49 | 73.55 | 837.41 | |||||
Normalized Net Income, 2 Yr. CAGR % | 20.81 | -40.25 | -76.36 | 89.43 | 656.27 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | -47.57 | -48.82 | -73.74 | 73.21 | 867.13 | |||||
Accounts Receivable, 2 Yr. CAGR % | 10.97 | 5.63 | 2.57 | 18.55 | 26.41 | |||||
Inventory, 2 Yr. CAGR % | -5.18 | -3.42 | 15.06 | 20.23 | 16.82 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | -9.27 | -13.29 | -14.09 | 7.48 | 21.6 | |||||
Total Assets, 2 Yr. CAGR % | 10.79 | 9.04 | 4.5 | 1.72 | -13.16 | |||||
Tangible Book Value, 2 Yr. CAGR % | 11.8 | 8.54 | -6.54 | -8.65 | -29.57 | |||||
Common Equity, 2 Yr. CAGR % | 10.85 | 7.85 | 3.88 | 1.07 | -22.51 | |||||
Cash From Operations, 2 Yr. CAGR % | 18.22 | -21.4 | -55.35 | -29.81 | 192.4 | |||||
Capital Expenditures, 2 Yr. CAGR % | -26.4 | -38.5 | 1.25K | 163.63 | -90.06 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 19.63 | -8.36 | 35.68 | -23.92 | -24.87 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 19.63 | -8.36 | 35.68 | -23.92 | -24.87 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 11.64 | 3.84 | -8.1 | -9.56 | -5.29 | |||||
Gross Profit, 3 Yr. CAGR % | 12.08 | 4.32 | -7.51 | -8.29 | -4.08 | |||||
EBITDA, 3 Yr. CAGR % | 22.15 | -29.35 | -28.63 | -10.26 | 150.86 | |||||
EBITA, 3 Yr. CAGR % | 23.33 | -31.41 | -25.53 | -8.54 | 163.89 | |||||
EBIT, 3 Yr. CAGR % | 24.71 | -34.78 | -19.99 | -1.2 | 187.99 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 9.56 | -62.13 | -52.45 | -17.08 | 227.53 | |||||
Net Income, 3 Yr. CAGR % | 9.56 | -62.13 | -52.45 | -17.08 | 227.53 | |||||
Normalized Net Income, 3 Yr. CAGR % | 18.68 | -26.98 | -57.33 | -12.08 | 156.5 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 6.51 | -62.64 | -54.33 | -17.14 | 224 | |||||
Accounts Receivable, 3 Yr. CAGR % | 4.1 | 8.32 | 4.38 | 13.2 | 17.65 | |||||
Inventory, 3 Yr. CAGR % | 1.03 | 1.55 | 1.97 | 18.97 | 15.76 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 41.01 | -9.98 | -14.44 | 0.78 | 7.19 | |||||
Total Assets, 3 Yr. CAGR % | 21.37 | 9.45 | 6.72 | 3.39 | -8.31 | |||||
Tangible Book Value, 3 Yr. CAGR % | 24.56 | 9.45 | -0.63 | -4.34 | -25.53 | |||||
Common Equity, 3 Yr. CAGR % | 22.39 | 8.66 | 6.33 | 2.17 | -14.7 | |||||
Cash From Operations, 3 Yr. CAGR % | 28.9 | -11.37 | -37.24 | -37.39 | 50.69 | |||||
Capital Expenditures, 3 Yr. CAGR % | 14.47 | -12.66 | 283.25 | 104.47 | 13.7 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 17.36 | -1.36 | 32.09 | -27.05 | 15.13 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 17.36 | -1.36 | 32.09 | -27.05 | 15.13 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 12.97 | 9.03 | -0.05 | -2.64 | -2.73 | |||||
Gross Profit, 5 Yr. CAGR % | 14.91 | 9.34 | 0.6 | -1.55 | -2.01 | |||||
EBITDA, 5 Yr. CAGR % | 46.35 | -8.23 | -15.02 | 4.82 | 36.58 | |||||
EBITA, 5 Yr. CAGR % | 41.71 | -12.34 | -12.6 | 6.55 | 38.08 | |||||
EBIT, 5 Yr. CAGR % | 17.82 | -17.84 | -8.49 | 12.26 | 40.88 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 12.98 | -16.62 | -36.96 | -30.38 | 56.7 | |||||
Net Income, 5 Yr. CAGR % | 12.98 | -16.62 | -36.96 | -30.38 | 56.7 | |||||
Normalized Net Income, 5 Yr. CAGR % | 18.8 | -6.04 | -37.28 | 0.6 | 34.76 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 6.95 | -20.66 | -39.16 | -31 | 54.87 | |||||
Accounts Receivable, 5 Yr. CAGR % | 9.88 | 13.75 | 3.48 | 12.3 | 12.69 | |||||
Inventory, 5 Yr. CAGR % | 5.64 | 7.29 | 6.42 | 8.65 | 7.67 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 19.82 | 15.64 | 15.65 | -3.37 | -1.53 | |||||
Total Assets, 5 Yr. CAGR % | 23.06 | 25.29 | 14.32 | 6.29 | -1.73 | |||||
Tangible Book Value, 5 Yr. CAGR % | 36.18 | 37.02 | 11.04 | 1.82 | -13.41 | |||||
Common Equity, 5 Yr. CAGR % | 30.91 | 32.03 | 14.62 | 5.56 | -6.31 | |||||
Cash From Operations, 5 Yr. CAGR % | 51.29 | 74.39 | -15.65 | -19.27 | 16.15 | |||||
Capital Expenditures, 5 Yr. CAGR % | -17.07 | -16.41 | 207.42 | 35.87 | -11.08 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 73.49 | 3.18 | 24.37 | -11.09 | 5.09 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 73.49 | 3.18 | 24.37 | -11.09 | 5.09 |
- Stock Market
- Equities
- VNDA Stock
- Financials Vanda Pharmaceuticals Inc.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















